

Titlepage

Baseline TyG index, myoglobin, and cerebral infarction history predict the onset of pulmonary hypertension in coronary artery disease patients after PCI treatment within a median of 4.5 years: a prospective cohort study

1 **Li Xie¹, Shilin Fu¹, Yuzheng Xu¹, Litong Ran¹, Jing Luo¹, Rongsheng Rao², Jianfei Chen¹, Shi-**
2 **Zhu Bian^{1*} and Dehui Qian^{1*}**

3 ¹Institute of Cardiovascular Diseases of PLA; Department of Cardiology, Xinqiao Hospital, Army
4 Medical University (Third Military Medical University).

5 ²Department of Ultrasonography, Xinqiao Hospital, Army Medical University (Third Military
6 Medical University).

7 *** Correspondence authors:**

8 Shi-Zhu Bian

9 bianshizhu@163.com

10 Dehui Qian

11 qiandehui@163.com

12 **Short running title: Baseline TyG predicts PH**

13 The number of the words of abstract: 247.

14 The number of the word of main text: 3274.

15 References: 46.

16 Tables:5.

17 **Keywords: TyG index; pulmonary hypertension; coronary artery disease; percutaneous**
18 **coronary intervention; echocardiography**

19

20 **Abstract**

21 **Aim:** To identify the predictive role of the TyG index for the onset of pulmonary hypertension in
22 patients with coronary artery disease (CAD) who underwent percutaneous coronary intervention
23 (PCI) treatment. **Methods:** We performed this prospective cohort study among CAD patients who
24 received PCI treatment in our center from July 2016 to October 2022. The baselines of
25 echocardiography at both cross-sections and blood biomarkers. A coronary angiography operation
26 was also performed. Within a median of 4.5 years of follow-up, the patients underwent
27 echocardiography to measure their pulmonary hypertension (PH). **Results:** Baseline BNP was
28 statistically higher in the PH patients ($p = 0.007$). The baseline myoglobin (MYO), was significantly
29 higher among PH patients ($p < 0.001$). Though the glucose level showed no difference between PH
30 and non-PH groups, the HDL-C was in a lower level in the PH group ($p = 0.033$). However, TyG
31 index showed no differences between PH and non-PH groups [6.95 (6.47-7.36) vs. 7.15 (6.49-7.96),
32 $p = 0.202$]. In the univariate regression, cerebral infarction history, right atria end-diastolic internal
33 diameter, MYO, triglyceride, HDL-C and TyG index ($p < 0.05$) were potential predictors for PH.
34 Finally, the adjusted logistic regression indicated that cerebral infarction history ($p = 0.39$), MYO (p
35 $= 0.044$) and TyG index ($p = 0.048$) were independent predictors of the onset of PH. **Conclusion:** PH
36 is prevalent in CAD patients after PCI treatment. The baseline TyG index, cerebral infarction history,
37 and MYO level were independent predictors for PH in CAD patients after PCI treatment.

38

39 **1 Introduction**

40 Insulin resistance (IR) has been considered a critical pathophysiological process in cardiometabolic
41 diseases and other cardiovascular diseases in various clinical and basic research (1,2). The
42 triglyceride-glucose (TyG) index is the product of fasting plasma glucose (FPG) and triglycerides
43 (TGs). It has been indicated to be a reliable surrogate marker of IR (3,4). Furthermore, it has been
44 indicated that the TyG index is well-correlated to the homeostasis model which is used to assess IR
45 (2,5,6). It has also been used as a marker and predictor for a variety of diseases, including major
46 adverse cardiovascular events (MACE) as well as atrial fibrillation (AF), over traditional risk factors
47 (5,7-9). The TyG index has been used widely because IR is a leading reason for the elevations of
48 triglyceride and glucose among healthy populations.

49 Among ST elevation myocardial infarction patients, the higher TyG index has been indicated to
50 increase the risk of major adverse cardiac and cerebrovascular events(7,10,11). Although a number of
51 the previous studies have indicated the associations between TyG index and vascular diseases, no
52 studies further identify the predictive role of the TyG index in pulmonary hypertension (PH) among
53 coronary artery disease (CAD) patients after PCI treatment (9,12-14).

54 The complications of CAD patients after PCI such as MACE and heart failure have received
55 sufficient attention (15-18). However, the effect of CAD on pulmonary circulation has not been
56 investigated widely, especially after patients received PCI treatment (19,20).

57 PH has been considered as one of the most common complications in patients with cardiovascular
58 diseases. PH is characterized with an elevated pulmonary arterial pressure (PAP) and significant
59 remodeling of pulmonary arterioles (21-23). PH is a clinical syndrome which is caused by various
60 etiologies resulting in modifications of function or structures of pulmonary vasculature, leading to the
61 rise of PAP and pulmonary vascular resistance (PVR) (21). It has been indicated that PH is the
62 primary reason for right heart failure, which may be a fatal complication in patients with
63 cardiovascular disease. The incidence of PH in various cardiovascular diseases has been reported to
64 be from 20 to 80%. Except in cases of congenital heart disease and dilated cardiomyopathy, PH was
65 frequently found in CAD patients (19). Recently, PH has also been recognized as a threat in
66 cardiovascular patients which may lead to fatigue, shortness of breath and even right heart failure and
67 death. Because the onset of PH among patients is often obscured by other diseases, when PH is
68 diagnosed, it may be in its later stage and difficult to treat. Thus, the early discovery and diagnosis of
69 PH is of great importance (24).

70 It is well known that PH is a multi-factorial and complex clinical syndrome which accompanies a
71 variety of diseases including heart failure, lung diseases, hypoxia and chronic thromboembolism
72 (22). PH in CAD patients after PCI has not been identified (25). We designed this study to identify
73 the predictive role of the TyG index in PH populations who suffers from CAD patients after PCI
74 operation treatments.

75 **2 Methods**

76 **2.1 Patients and Study Design**

77 All consecutive patients who were clinically diagnosed with CAD in our center from July 2016 and
78 July 2019 were included into this study according to the inclusion and exclusion criteria. The follow-
79 up was finished in October 2022. The inclusion criteria were: aged from 18-80 years, and clinically
80 diagnosed with unstable angina. A patient with one of the following diseases including aortic

81 aneurysm, chronic kidney diseases, infections, congenital heart diseases, cardiac valve diseases,
82 connective tissue diseases, and cancer. A patient who has received PCI or coronary artery bypass
83 graft previously has also been excluded.

84 Finally, a total of 247 patients with CAD were enrolled. Upon admission, the patients' laboratory and
85 demographic data as well as the disease' history have been tested and recorded. Our study conforms
86 to the Declaration of Helsinki. The study has been approved by our ethical committee of Xinqiao
87 Hospital, Third Military Medical University (Army Military Medical University). The patients were
88 familiarized with the procedure and contents of the study and provided written informed consent.

89 Venous blood samples were obtained from patients on admission prior to coronary intervention. Both
90 serum and plasma samples were obtained and placed on ice. After they were centrifuged within 30
91 min, they were stored at -70°C for the further test.

92 **2.2 The Assessments of CAD Severity for each patient**

93 We have performed a scheduled coronary angiography (CAG) for each patient according to standard
94 techniques. At least two of our trained interventional cardiologists. CAD in our center was defined as
95 following: at least a single-vessel with a stenosis $\geq 50\%$.

96 **2.3 Biochemical Parameters**

97 We have obtained venous blood samples from CAD patients in the early morning after at least 12
98 hours' overnight fast.

99 We have performed the biochemical examinations. We have tested the levels of blood glucose
100 (fasting blood glucose, FBG) and lipids including total cholesterol (TC), high-density lipoprotein
101 cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG)
102 concentrations by using Beckman Coulter AU5800 system (USA). Furthermore, we have also
103 detected the liver and renal functions with the same machine above.

104 We have also measured the plasma UA with Roche enzymatic assays (Roche Diagnostics GmbH,
105 Mannheim, Germany). Furthermore, plasma creatinine (Cr) concentration was also measured by
106 using Hitachi 7600 autoanalyzer (Hitachi, Tokyo, Japan) via enzymatic assay. The blood urea
107 nitrogen concentration (BUN) was also measured (FERENE methods, Beckman AU5821).

108 Finally, we have tested the electrolytes including sodium concentration (Na^+), serum calcium
109 concentration (Ca^{2+}), phosphate concentration (P), serum potassium concentration (K^+) and chloride
110 ion (Cl^-) were also measured.

111 The levels of myohemoglobin (MYO), creatine kinase isoenzyme-MB (CK-MB) and cardiac
112 troponin I (TnI) in serum were measured using standard assay kits and a Geteln 110 (Jiangsu, China)
113 automatic chemiluminescence immunoassay analyzer, and the plasma level of brain natriuretic
114 peptide (BNP) was also measured according to the manufacturer's instructions using a Geteln 110
115 (Jiangsu, China) automatic chemiluminescence immunoassay analyzer.

116 **2.4 Clinical data collection**

117 The patients were followed-up by our physicians. We used a standardized self-report questionnaire
118 form to record patients' data including demographic information and diseases history as well as the
119 medication use. Height and weight were also measured. The history of smoking status and drinking.

120 The systolic blood pressure (SBP), heart rate (HR) and diastolic blood pressure (DBP) were
121 measured on the right arm in a sitting position after sufficient rest.

122 **2.5 Echocardiography examinations**

123 Both at the baseline and follow-up cross-sections, echocardiography examinations have been
124 performed by our trained technicians with an ultrasonography workstation (CX50, Philips, USA;
125 probe: S5). The patients were positioned in a supine position after a rest of ten min. The technicians
126 have measured and recorded the end-diastolic internal diameters of the left and right atria (LAD and
127 RAD). As regulation, the end-diastolic internal diameters of left and right ventricles (LVDD and
128 RVD) have also been measured and recorded. In the next step, the thickness of the interventricular
129 septum (IVS) and left ventricular posterior wall (LVPW) have also been evaluated and recorded. The
130 fractional shortening (FS), stroke volume (SV) and ejection fraction (LVEF) has been measured and
131 calculated. Finally, the tricuspid regurgitation area (TRA), TR velocity (TRV) which was used to
132 calculate the PAP, and TR pressure.

133 **2.6 Variables**

134 We measured and calculated the systolic PAP (sPAP) by using the modified Bernoulli equation using
135 the tricuspid systolic jet according to the American Society of Echocardiography:

$$\text{sPAP} = 4 \times (\text{TRV})^2 + \text{estimated right atrial pressure}$$

136 The estimated right atrial pressure was recorded as 5 mmHg (normal right atrium size), 10 mmHg
137 (mildly enlarged right atrium size), and 15 mmHg (significantly enlarged right atrium size) in
138 according to the right atrium size.

139 An sPAP >35 mmHg was defined as PH. In contrast, the patients with sPAP <35 mmHg were
140 included in the non-PH group According to the American Society of Echocardiography and other
141 studies.

142 **2.7 Follow-up**

143 The follow-up at the outpatient department was performed by our doctors, including Li Xie, Shi-Zhu
144 Bian, Dehui Qian, Shilin Fu and Jianfei Chen, with an objective case report form, and regular
145 examinations for the CAD patients. Furthermore, the examination of echocardiograms was performed
146 by a technician, Dr. Rongsheng Rao.

147 **2.8 Statistical Analysis**

148 All of our statistical analyses were employed with SPSS software (version 26.0, IBM Corp.,
149 America). Continuous normalized distribution variables are expressed as mean \pm standard deviation
150 (SD) and were compared using Students' test between two groups. The non-normalized distributed
151 data are summarized as medians (interquartile ranges). Each categorical variable was expressed in
152 case and proportions. The differences of the non-normalized distributed data between the PH group
153 and non-PH group were analyze by using a Kruskal-Wallis nonparametric test. The correlations
154 between baseline parameters and sPAP were identified by using Spearman's correlation analyses.
155 The potential predictors were analyzed by univariate and multivariate regressions. The backward
156 stepwise logistic regression models were used to identify the predictors for the onset of PH in CAD
157 patients. Statistical significance was defined as a p value is less than 0.05.

158 **3 Results**

159 Within a median of 4.5 years' follow-up, the incidence of PH was 8.91%. The demographic data
160 were shown in table 1. The LAD and LVDD increased dramatically while the LVEF decreased
161 significantly ($p < 0.001$). Furthermore, the right heart structure also changed significantly (table 2).
162 However, at the baseline cross-section, no significant differences were found between the PH and
163 non-PH groups among LAD, LVDD, RAD, RVD, LVEF and SV (all p values are greater than 0.05).
164 The biomarker of heart failure, BNP, was dramatically higher in the PH population than in the non-
165 PH ones (68.00 [18.05-196.00] vs. 174.00 [76.25-447.75], $p = 0.007$). The biomarkers for cardiac
166 injury, including TNI and CK-MB, showed no significant differences between PH and non-PH
167 groups ($p > 0.05$). However, baseline MYO was dramatically higher in the PH group than that in the
168 non-PH populations (56.30 [42.65-77.25] vs. 76.30 [64.38-126.35] ng/ml, $p < 0.001$). We also found
169 that HDL-C (1.06 [0.870-1.26] vs. 0.915 [0.770-1.071] mmol/L) was significantly lower in the PH
170 group than that in the non-PH group ($p = 0.033$). However, the TyG index showed no significant
171 difference between PH patients and non-PH ones (6.95 [6.47-7.36] vs. 7.15 [6.49-7.96], $p = 0.202$).
172 The basic parameters, including HR, SBP and DBP, showed similar levels between PH group and
173 non-PH group ($p > 0.05$) (table2-3).

174 In the next step, we analyzed the correlation between sPAP and all of the parameters. The
175 demographic variables, including BMI and age, showed no close association with sPAP. Whilst we
176 found that the baselines of TRA ($r = 0.151$, $p = 0.017$) and TRV ($r = 0.156$, $p = 0.014$) were
177 significantly positively correlated with sPAP, other baseline hemodynamics parameters showed no
178 close relationship with sPAP (table 4).

179 In the univariate regression, we performed analyses with each variable. We identified that cerebral
180 infarction history ($\beta = 0.991$, odds ratio (OR): 2.694, 95% confidence interval (CI): 1.085-6.690, $p =$
181 0.033), LAD ($\beta = 0.074$, OR: 1.077, 95% CI: 0.987- 1.174, $p = 0.095$), RAD ($\beta = 0.055$, OR: 1.057,
182 95% CI: 0.976-1.144, $p =$), MYO ($\beta = 0.007$, OR: 1.007, 95% CI: 1.001-1.013, $p = 0.024$), TG ($\beta =$
183 0.304, OR: 1.355, 95% CI: 1.062-1.730, $p = 0.015$), HDL-C ($\beta = -1.744$, OR: 0.175, 95% CI: 0.027-
184 1.115, $p = 0.065$), HbA1c ($\beta = 0.288$, OR: 1.334 , 95% CI: 0.975-1.825, $p = 0.071$) and TyG index (β
185 = 0.628, OR: 2.389, 95% CI: 1.308-4.363, $p = 0.005$) were potential predictors/risk factors for PH in
186 CAD patients after PCI treatment (table 5).

187 Finally, the adjusted logistic regression indicated that cerebral infarction history ($\beta = 0.990$, OR:
188 2.690, 95% CI: 1.054-6.871, $p = 0.039$), MYO ($\beta = 0.006$, OR: 1.006, 95% CI: 1.000-1.012, $p =$
189 0.044), and TyG ($\beta = 0.636$, OR: 1.889, 95% CI: 1.006-3.546, $p = 0.048$) were independent predictors
190 of the onset of PH (table 6).

191 **4 Discussion**

192 We performed a prospective cohort study within a median of 4.5 years' follow-up. The primary
193 endpoint focused on the onset of PH, which is frequently accompanied with various cardiovascular
194 diseases. However, there have been few studies focusing on PH in CAD patients who have received
195 PCI treatment. We analyzed the associations between the baselines of demographic data, renal
196 functions, biomarkers for cardiac injury, serum lipids, and glucose. We have identified that the
197 history of cerebral infarction, the TyG index baseline, and the MYO baseline were independent
198 predictors for PH in CAD patients who received PCI treatment after 4.5 years.

199 **4.1 PH in CAD patients after treatment with PCI**

200 According to the previous guidelines and studies, PH refers to mean PAP (mPAP) >25mmHg at sea
201 level measured by right heart catheterization (22). However, in the latest guidelines, the cutoff value
202 of mPAP for PH has been updated to 20 mmHg, which may include more PH patients who were not
203 diagnosed as PH in the past (22). Thus, a higher incidence of PH will be diagnosed in various
204 diseases, and the early diagnosis and prevention of PH will prevent it developing into the advanced
205 stage. The importance of PH in various cardiovascular diseases has been promoted. However, the
206 diagnosis of PH evaluated by echocardiography has not yet been updated (26). Thus, in our present
207 study, the cutoff of sPAP measured by echocardiography had not been revised and updated, and
208 needs to be further studied in clinical practice. In future studies, we may investigate PH in
209 accordance with the latest guidelines for the cut-off of sPAP evaluated by non-invasive
210 echocardiography.

211 In our present study, the PH which accompanied CAD may be classified as PH due to left heart
212 diseases (19,22,27). Left heart-related diseases are one of the most frequent causes of PH. However,
213 the clinical prevalence data of left heart disease-related PH has not been uncovered (19,27). The
214 incidence of PH has varied in different studies due to differing evaluation methods and criteria for
215 PH diagnosis.

216 As discussed above, PH has been recognized as one of the most frequent complications of various
217 cardiovascular diseases (28-31). However, in CAD patients, few studies have focused on PH
218 complications. Incidence of PH was 8.91% among 247 CAD patients who received PCI treatment in
219 our study. This incidence may be much higher if the cutoff is updated in the future (22). Though PH
220 was not as significant as heart failure in CAD patients, it may affect right heart function or induce
221 symptoms. PH is a common complication of CAD patients which has previously not been widely
222 investigated and treated. Thus, PH should be given sufficient attention in clinical practice for CAD
223 patient treatment and management.

224 **4.2 Association of IR/TyG index and cardiovascular diseases**

225 It has been indicated that IR is involved in the pathogenesis of various of diseases including
226 atherosclerotic cardiovascular diseases (2). Diabetes is considered a primary risk factor of
227 cardiovascular diseases, however, the association between diabetes and PH has not been confirmed
228 (32). Though IR has been widely indicated to be a risk factor for a number of cardiovascular diseases
229 including MACE and atherosclerosis (1,2,12,33), few studies have reported the roles of IR in PH,
230 especially in CAD patients. The novel TyG index, a simple surrogate marker of IR, has been widely
231 used as a marker/risk factor/predictor for a large number of cardiovascular diseases (5,34-36). A
232 higher TyG index has been indicated to be correlated to hypertension (37). They found that the
233 hypertension was significantly more likely in the patients with the highest level of TyG index than in
234 the lowest level of TyG index patients (38). However, these results should be studied in future large-
235 scale prospective cohort studies. In addition, further studies are needed to elucidate the potential
236 pathophysiological mechanisms underlying the association between the TyG index and hypertension.
237 Increasing evidence indicates that a higher TyG index or a higher level of TG and FBG levels
238 increase atherosclerosis risk, including peripheral artery disease and arterial stiffness (39).
239 Triglycerides have been indicated to be independent risk factors for CVD. Uncontrolled diabetes
240 and/or hyperlipidemia has been indicated to result to high level of TyG index, which is associated
241 with symptomatic patients' CVD (35).

242 **4.3 TyG and PH in CAD patients after PCI treatment**

243 Few researchers have focused on the complications of pulmonary vessels. Though PH has attracted
244 an increasing amount of attention from clinical physicians and researchers, PH's clinical
245 characteristics and risk factors in CAD patients who have received PCI treatment have not been
246 widely investigated (19,20,24,25,40). The roles of the TyG index in outcomes of patients who
247 underwent PCI treatment have been partly reported (7,10,41,42). The associations between TyG
248 index and poor prognosis in patients with acute ST-elevation myocardial infarction after PCI have
249 also been indicated in previous studies(7,10). However, the potential role of the TyG index as a
250 predictor of PH in CAD patients after PCI treatment has not been studied. Thus, we focused on the
251 predictive role of baseline TyG for PH in CAD patients who have received PCI treatment, within a
252 median of 4.5 years' follow-up. In the present study, PH patients were indicated to be characterized
253 with a higher level of TyG index, but this was not statistically significant. In the univariate
254 regression, we found that the TyG index was a potential predictive factor of PH. Additionally, the
255 adjusted regression indicated that the higher baseline TyG index was an independent predictor for the
256 onset of PH in CAD patients who underwent PCI treatment. Though no evidence indicated that PH is
257 caused by IR or abnormal metabolism of lipids or glucose, PH may be the results of IR in
258 cardiovascular diseases (1,2). The patients in our study were CAD patients who may have also
259 suffered from left heart failure, and the PH found may have been caused by this left heart failure.
260 Another possibility is that the IR or TyG index may be associated with PH via its roles in the heart or
261 coronary arteries (43-45). Furthermore, it is also possible that IR has a detrimental effect on
262 pulmonary vessels, increasing the remodeling of pulmonary vessels and PVR (44,45).

263 In clinical practice, a physician usually examines fasting glucose level to identify patients with high-
264 risk, especially cardiovascular disease patients (11,46). The TyG index may also be valuable for
265 prognostic cardiovascular disease risk stratifications, and may have a higher diagnostic significance
266 than FBG and TG levels (11,46). However, PH has been indicated to be a progressively and
267 dynamically progresses disorder. Thus, the TyG index as a prognostic marker can be easily biased by
268 hyperlipidemia and diabetes.

269 **4.4 Other predictors for PH in CAD patients**

270 It is of great importance to identify the risk factors/predictors of PH as a prognosis of CAD patients
271 who underwent PCI treatment for effective prevention. We have identified that beside the TyG index,
272 the history of cerebral infarction and the baseline level of MYO were also independent predictors for
273 PH in CAD patients. To the best of our knowledge, this is the first study to identify that the history of
274 cerebral infarction was an independent risk factor for PH in CAD patients. This may be explained by
275 the comorbidity of CVD and PH. It is worth noting that some of the patients included in our study
276 were at risk of CAD because they had a previous history of CVD. Furthermore, baseline MYO was
277 also indicated to be an independent risk factor for the onset of PH in CAD patients after PCI
278 treatment. The above results suggest that myocardial injury may lead to chronic left heart failure,
279 which is a common reason for PH.

280 **5 Conclusion**

281 PH is prevalent in CAD patients after PCI treatment. The baseline TyG index, cerebral infarction
282 history, and MYO level were independent predictors for PH in CAD patients after PCI treatment.

283

284 **6 Conflict of Interest**

285 We declare that the research was conducted without any commercial or financial relationships that
286 could be construed as a potential conflict of interest.

287 **7 Author Contributions**

288 DQ and SZB participated in the design of the study. The manuscript and the statistical analyses were
289 performed by LX, DQ and SZB. DQ reviewed and revised this manuscript critically for important
290 intellectual content. Echocardiography examinations were performed by our technician RR. The
291 sPAP-related assessments were recorded and analyzed by YX and LX. Clinical data and laboratory
292 examinations data were performed and recorded by LX, LR and JL. Other laboratory data and
293 patients' follow-up were carried out by JC, YX and SF. The CAG operations were performed by LX,
294 JC and DQ.

295 **8 Funding**

296 The present research is supported by the “Senior Medical Talents Program of Chongqing for
297 Yong and Middle-aged” to Shi-Zhu Bian, “Miaopu” Young Scientists Program from Army
298 Military Medical University (2019R046) and Basic Research Program from Army Military
299 Medical University (2020D050).

300 **9 Acknowledgments**

301 The authors would like to thank all the individuals who participated in this study for their supports.

302

303 **10 References**

- 304 [1] R. Rojas-Humpire, M. Olarte-Durand, S. Medina-Ramirez, R. Gutierrez-Ajalcrina, J.F. Canaza,
305 and S. Huancahuire-Vega, Insulin Resistance Indexes as Biomarkers of Lifetime Cardiovascular Risk
306 among Adults from Peru. *J Nutr Metab* 2021 (2021) 6633700.
- 307 [2] M.A. Hill, Y. Yang, L. Zhang, Z. Sun, G. Jia, A.R. Parrish, and J.R. Sowers, Insulin resistance,
308 cardiovascular stiffening and cardiovascular disease. *Metabolism* 119 (2021) 154766.
- 309 [3] H. Li, Y. Zuo, F. Qian, S. Chen, X. Tian, P. Wang, X. Li, X. Guo, S. Wu, and A. Wang,
310 Triglyceride-glucose index variability and incident cardiovascular disease: a prospective cohort
311 study. *Cardiovasc Diabetol* 21 (2022) 105.
- 312 [4] Q. Zhao, T.Y. Zhang, Y.J. Cheng, Y. Ma, Y.K. Xu, J.Q. Yang, and Y.J. Zhou, Triglyceride-
313 Glucose Index as a Surrogate Marker of Insulin Resistance for Predicting Cardiovascular Outcomes

- 314 in Nondiabetic Patients with Non-ST-Segment Elevation Acute Coronary Syndrome Undergoing
315 Percutaneous Coronary Intervention. *J Atheroscler Thromb* 28 (2021) 1175-1194.
- 316 [5] S.P. Araujo, L.L. Juvanhol, J. Bressan, and H.H.M. Hermsdorff, Triglyceride glucose index: A
317 new biomarker in predicting cardiovascular risk. *Prev Med Rep* 29 (2022) 101941.
- 318 [6] X. Zeng, D. Han, H. Zhou, Y. Xue, X. Wang, Q. Zhan, Y. Bai, X. Huang, Q. Zeng, H. Zhang, Z.
319 Ma, H. Ren, and D. Xu, Triglyceride-Glucose Index and Homeostasis Model Assessment-Insulin
320 Resistance in Young Adulthood and Risk of Incident Congestive Heart Failure in Midlife: The
321 Coronary Artery Risk Development in Young Adults Study. *Front Cardiovasc Med* 9 (2022) 944258.
- 322 [7] Y. Ling, C. Fu, Q. Fan, J. Liu, L. Jiang, and S. Tang, Triglyceride-Glucose Index and New-Onset
323 Atrial Fibrillation in ST-Segment Elevation Myocardial Infarction Patients After Percutaneous
324 Coronary Intervention. *Front Cardiovasc Med* 9 (2022) 838761.
- 325 [8] L. Xu, M. Wu, S. Chen, Y. Yang, Y. Wang, S. Wu, and Y. Tian, Triglyceride-glucose index
326 associates with incident heart failure: A cohort study. *Diabetes Metab* 48 (2022) 101365.
- 327 [9] M.I. Hayiroglu, T. Cinar, V. Cicek, A. Palice, G. Ayhan, and A.I. Tekkesin, The Triglyceride-
328 Glucose Index Can Predict Long-Term Major Adverse Cardiovascular Events in Turkish Patients
329 With High Cardiovascular Risk. *J Lipid Atheroscler* 11 (2022) 280-287.
- 330 [10] B. Yu, Y. Mo, X. Hu, W. Wang, J. Liu, J. Jin, Z. Lun, C.R. Luo Bu, H. Dong, and Y. Zhou,
331 Triglyceride-glucose index is associated with quantitative flow ratio in patients with acute ST-
332 elevation myocardial infarction after percutaneous coronary intervention. *Front Cardiovasc Med* 9
333 (2022) 1002030.
- 334 [11] E. Luo, D. Wang, G. Yan, Y. Qiao, B. Liu, J. Hou, and C. Tang, High triglyceride-glucose index
335 is associated with poor prognosis in patients with acute ST-elevation myocardial infarction after
336 percutaneous coronary intervention. *Cardiovasc Diabetol* 18 (2019) 150.
- 337 [12] O. Sajdeya, A. Beran, M. Mhanna, A. Alharbi, C. Burmeister, Z. Abuhelwa, S.E. Malhas, Y.
338 Khader, W. Sayeh, R. Assaly, and G.V. Moukarbel, Triglyceride Glucose Index for the Prediction of
339 Subclinical Atherosclerosis and Arterial Stiffness: A Meta-analysis of 37,780 Individuals. *Curr Probl*
340 *Cardiol* 47 (2022) 101390.
- 341 [13] F.O. Karadeniz, E.A. Sancaktepe, and Y. Karadeniz, High Triglyceride-Glucose Index is
342 Associated With Poor Prognosis in Patients With Acute Coronary Syndrome in Long-Term Follow-
343 Up. *Angiology* (2022) 33197221124763.
- 344 [14] R. Huang, Z. Wang, J. Chen, X. Bao, N. Xu, S. Guo, R. Gu, W. Wang, Z. Wei, and L. Wang,
345 Prognostic value of triglyceride glucose (TyG) index in patients with acute decompensated heart
346 failure. *Cardiovasc Diabetol* 21 (2022) 88.
- 347 [15] R. Yokoyama, Y. Kanzaki, T. Watanabe, K. Yamamura, T. Komori, Y. Takeda, O. Nakajima,
348 K. Sohmiya, and M. Hoshiga, Prevalence and Risk Factors of Silent Cerebral Microbleeds in Patients
349 with Coronary Artery Disease. *J Stroke Cerebrovasc Dis* 31 (2022) 106211.

- 350 [16] M. Sun, H. Guo, Y. Wang, and D. Ma, Association of triglyceride glucose index with all-cause
351 and cause-specific mortality among middle age and elderly US population. *BMC Geriatr* 22 (2022)
352 461.
- 353 [17] J. Vahatalo, L. Holmstrom, L. Pakanen, K. Kaikkonen, J. Perkiomaki, H. Huikuri, and J.
354 Junttila, Coronary Artery Disease as the Cause of Sudden Cardiac Death Among Victims < 50 Years
355 of Age. *Am J Cardiol* 147 (2021) 33-38.
- 356 [18] S. Chen, Y. Dong, M.G. Kiuchi, J. Wang, R. Li, Z. Ling, T. Zhou, Z. Wang, M. Martinek, H.
357 Purerfellner, S. Liu, and M.W. Krucoff, Coronary Artery Complication in Kawasaki Disease and the
358 Importance of Early Intervention : A Systematic Review and Meta-analysis. *JAMA Pediatr* 170
359 (2016) 1156-1163.
- 360 [19] L. Huang, L. Pang, Q. Gu, T. Yang, W. Li, R. Quan, W. Su, W. Wu, F. Tang, X. Zhu, J. Shen, J.
361 Sun, G. Shan, C. Xiong, S. Huang, and J. He, Prevalence, risk factors, and survival associated with
362 pulmonary hypertension and heart failure among patients with underlying coronary artery disease: a
363 national prospective, multicenter registry study in China. *Chin Med J (Engl)* 135 (2022) 1837-1845.
- 364 [20] M. Asker, S. Asker, U. Kucuk, H.O. Kucuk, and B. Ozbay, Relationship between coronary
365 artery disease and pulmonary arterial pressure in patients with chronic obstructive pulmonary disease.
366 *Int J Clin Exp Med* 7 (2014) 5837-41.
- 367 [21] S.E. Orfanos, and G. Giannakoulas, Pulmonary Hypertension: Current Diagnosis, Approach and
368 Treatment at the Dawn of the New European Guidelines. *J Clin Med* 11 (2022).
- 369 [22] M. Humbert, G. Kovacs, M.M. Hoeper, R. Badagliacca, R.M.F. Berger, M. Brida, J. Carlsen,
370 A.J.S. Coats, P. Escribano-Subias, P. Ferrari, D.S. Ferreira, H.A. Ghofrani, G. Giannakoulas, D.G.
371 Kiely, E. Mayer, G. Meszaros, B. Nagavci, K.M. Olsson, J. Pepke-Zaba, J.K. Quint, G. Radegran, G.
372 Simonneau, O. Sitbon, T. Tonia, M. Toshner, J.L. Vachiery, A. Vonk Noordegraaf, M. Delcroix, S.
373 Rosenkranz, and E.E.S.D. Group, 2022 ESC/ERS Guidelines for the diagnosis and treatment of
374 pulmonary hypertension. *Eur Respir J* (2022).
- 375 [23] A. Boucly, J. Weatherald, L. Savale, X. Jais, V. Cottin, G. Prevoit, F. Picard, P. de Groote, M.
376 Jevnikar, E. Bergot, A. Chaouat, C. Chabanne, A. Bourdin, F. Parent, D. Montani, G. Simonneau, M.
377 Humbert, and O. Sitbon, Risk assessment, prognosis and guideline implementation in pulmonary
378 arterial hypertension. *Eur Respir J* 50 (2017).
- 379 [24] Y. Yuan, Y. Zhang, X. Zhang, Y. Yu, B. Li, P. Wang, H. Li, Y. Zhao, C. Shen, and Z. Wang,
380 Deciphering the genetic and modular connections between coronary heart disease, idiopathic
381 pulmonary arterial hypertension and pulmonary heart disease. *Mol Med Rep* 14 (2016) 661-70.
- 382 [25] M. Ogiso, N. Serizawa, K. Kamishima, J. Yamaguchi, and N. Hagiwara, Percutaneous coronary
383 intervention for left main compression syndrome due to severe idiopathic pulmonary arterial
384 hypertension: one year follow-up using intravascular imaging. *Intern Med* 54 (2015) 801-4.
- 385 [26] I.N. Mansour, R.M. Lang, W.M. Aburuwaida, N.M. Bhave, and R.P. Ward, Evaluation of the
386 clinical application of the ACCF/ASE appropriateness criteria for stress echocardiography. *J Am Soc*
387 *Echocardiogr* 23 (2010) 1199-204.

- 388 [27] T. Gaisl, C. Schlatzer, E.I. Schwarz, M. Possner, J. Stehli, N.A. Sievi, C.F. Clarenbach, D. Dey,
389 P.J. Slomka, P.A. Kaufmann, and M. Kohler, Coronary artery calcification, epicardial fat burden, and
390 cardiovascular events in chronic obstructive pulmonary disease. *PLoS One* 10 (2015) e0126613.
- 391 [28] N. Hirani, N.W. Brunner, A. Kapasi, G. Chandy, L. Rudski, I. Paterson, D. Langleben, S.
392 Mehta, L. Mielniczuk, and C.C.P.H. Committee, Canadian Cardiovascular Society/Canadian
393 Thoracic Society Position Statement on Pulmonary Hypertension. *Can J Cardiol* 36 (2020) 977-992.
- 394 [29] Z. Dai, G. Lai, Z. Chen, Y. Li, X. Chen, and G. Lyu, Double Doppler Tei index combined with
395 lung ultrasound to evaluate the right ventricular function and lung condition in neonates with
396 pulmonary hypertension. *J Clin Ultrasound* (2022).
- 397 [30] K. Sree Raman, R. Shah, M. Stokes, A. Walls, R.J. Woodman, R. Ananthakrishna, J.G. Walker,
398 S. Proudman, P.M. Steele, C.G. De Pasquale, D.S. Celermajer, and J.B. Selvanayagam, Left
399 ventricular ischemia in pre-capillary pulmonary hypertension: a cardiovascular magnetic resonance
400 study. *Cardiovasc Diagn Ther* 10 (2020) 1280-1292.
- 401 [31] E. Boxhammer, V. Paar, P. Jirak, C. Koller, O. Demirel, S. Eder, C. Reiter, J. Kammler, J.
402 Kellermair, M. Hammerer, H. Blessberger, C. Steinwender, U.C. Hoppe, and M. Lichtenauer, Main
403 pulmonary artery diameter in combination with cardiovascular biomarkers. New possibilities to
404 identify pulmonary hypertension in patients with severe aortic valve stenosis? *Minerva Med* (2022).
- 405 [32] P.W. Wilson, Diabetes mellitus and coronary heart disease. *Am J Kidney Dis* 32 (1998) S89-
406 100.
- 407 [33] Y. Zhou, Y. Pan, H. Yan, Y. Wang, Z. Li, X. Zhao, H. Li, X. Meng, C. Wang, L. Liu, and Y.
408 Wang, Triglyceride Glucose Index and Prognosis of Patients With Ischemic Stroke. *Front Neurol* 11
409 (2020) 456.
- 410 [34] S. Han, C. Wang, F. Tong, Y. Li, Z. Li, Z. Sun, and Z. Sun, Triglyceride glucose index and its
411 combination with the Get with the Guidelines-Heart Failure score in predicting the prognosis in
412 patients with heart failure. *Front Nutr* 9 (2022) 950338.
- 413 [35] Z. Teng, J. Feng, Y. Dong, J. Xu, X. Jiang, H. Chen, Q. Qi, R. Li, W. Chen, and P. Lv,
414 Triglyceride glucose index is associated with cerebral small vessel disease burden and cognitive
415 impairment in elderly patients with type 2 diabetes mellitus. *Front Endocrinol (Lausanne)* 13 (2022)
416 970122.
- 417 [36] S. Ozbicer, G. Yuksel, and O. Deniz Urgun, Triglyceride glucose index is independently
418 associated with aortic intima-media thickness in patients without known atherosclerotic
419 cardiovascular disease or diabetes. *Diab Vasc Dis Res* 19 (2022) 14791641221136203.
- 420 [37] N. Emlek, and C. Aydin, The relationship between nondipper hypertension and triglyceride
421 glucose index. *Blood Press Monit* (2022).
- 422 [38] R. Zheng, and Y. Mao, Triglyceride and glucose (TyG) index as a predictor of incident
423 hypertension: a 9-year longitudinal population-based study. *Lipids Health Dis* 16 (2017) 175.
- 424 [39] I. Lambrinouadaki, M.V. Kazani, E. Armeni, G. Georgiopoulos, K. Tampakis, D. Rizos, A.
425 Agoulea, G. Kaparos, A. Alexandrou, and K. Stamatelopoulos, The TyG Index as a Marker of

- 426 Subclinical Atherosclerosis and Arterial Stiffness in Lean and Overweight Postmenopausal Women.
427 *Heart Lung Circ* 27 (2018) 716-724.
- 428 [40] P. Genereux, Pulmonary Hypertension and Aortic Stenosis: A Piece of the Puzzle. *J Am Coll*
429 *Cardiol* 80 (2022) 1614-1616.
- 430 [41] S. Xiong, Q. Chen, Z. Zhang, Y. Chen, J. Hou, C. Cui, L. Cheng, H. Su, Y. Long, S. Yang, L.
431 Qi, X. Chen, H. Liu, and L. Cai, A synergistic effect of the triglyceride-glucose index and the
432 residual SYNTAX score on the prediction of intermediate-term major adverse cardiac events in
433 patients with type 2 diabetes mellitus undergoing percutaneous coronary intervention. *Cardiovasc*
434 *Diabetol* 21 (2022) 115.
- 435 [42] F. Ozkalayci, A. Karagoz, C.Y. Karabay, I.H. Tanboga, E. Turkyilmaz, M. Saygi, and V.
436 Oduncu, Prognostic value of triglyceride/glucose index in patients with ST-segment elevation
437 myocardial infarction. *Biomark Med* 16 (2022) 613-622.
- 438 [43] N. Hijioka, M. Kamioka, Y. Matsumoto, M. Nodera, S. Yamada, T. Kaneshiro, A. Yoshihisa, T.
439 Ishida, and Y. Takeishi, Clinical impact of insulin resistance on pulmonary vein isolation outcome in
440 patients with paroxysmal atrial fibrillation. *J Cardiovasc Electrophysiol* 30 (2019) 479-486.
- 441 [44] R.T. Zamanian, G. Hansmann, S. Snook, D. Lilienfeld, K.M. Rappaport, G.M. Reaven, M.
442 Rabinovitch, and R.L. Doyle, Insulin resistance in pulmonary arterial hypertension. *Eur Respir J* 33
443 (2009) 318-24.
- 444 [45] N. Naderi, P. Boobejame, H. Bakhshandeh, A. Amin, S. Taghavi, and M. Maleki, Insulin
445 resistance in pulmonary arterial hypertension, is it a novel disease modifier? *Res Cardiovasc Med* 3
446 (2014) e19710.
- 447 [46] X. Xu, R. Huang, Y. Lin, Y. Guo, Z. Xiong, X. Zhong, X. Ye, M. Li, X. Zhuang, and X. Liao,
448 High triglyceride-glucose index in young adulthood is associated with incident cardiovascular
449 disease and mortality in later life: insight from the CARDIA study. *Cardiovasc Diabetol* 21 (2022)
450 155.
- 451

452

453 **11. Abbreviations**

454 AF: arial fibrillation;

455 ACEI: angiotensin converting enzyme inhibitor;

456 ARB: angiotensin receptor blocker;

457 BNP: B-type natriuretic peptide;

458 BUN: urea nitrogen concentration;

459 CAD: coronary artery disease.

460 CAG: coronary angiography;

461 Ca²⁺: serum calcium concentration;

462 CCB: calcium channel blockers;

463 CI: Confidence interval;

464 CK-MB: Creatine kinase-MB;

465 Cl⁻: chloride ion;

466 Cr: concentration of plasma creatinine;

467 DBP: diastolic blood pressure;

468 FBG: fasting blood glucose;

469 FS: fractional shortening

470 HDL-C: high-density lipoprotein cholesterol;

471 HR: heart rate;

472 IR: insulin resistance;

473 K⁺: serum potassium concentration;

474 LAD: end-diastolic internal diameter of the left atria;

475 LDL-C: low-density lipoprotein cholesterol;

476 LVDD: end-diastolic internal diameter of left ventricle;

477 LVEF: ejection fraction of left ventricle

478 LVPW: left ventricular posterior wall
479 MACE: major adverse cardiovascular events;
480 MACCE: major adverse cardiac and cerebrovascular events;
481 MYO: myoglobin;
482 Na⁺: sodium concentration;
483 OR: odds ratio;
484 P: phosphate concentration;
485 PAP: pulmonary arterial pressure;
486 PH: pulmonary hypertension;
487 PCI: percutaneous coronary intervention;
488 RAD: end-diastolic internal diameter of right atria;
489 RVD: end-diastolic internal diameter of right ventricle;
490 SBP: systolic blood pressure;
491 STEMI: ST elevation myocardial infarction;
492 T2DM: diabetes mellitus type 2;
493 TG: triglyceride;
494 TNI: Troponin;
495 TR: tricuspid regurgitation
496 TRA: TR area
497 TRV: TR velocity
498 TyG index: triglyceride-glucose index;
499
500
501
502
503
504

- 505 1. Rojas-Humpire R, Olarte-Durand M, Medina-Ramirez S, Gutierrez-Ajalcrina R, Canaza JF,
506 Huancahuire-Vega S. Insulin Resistance Indexes as Biomarkers of Lifetime Cardiovascular
507 Risk among Adults from Peru. *J Nutr Metab* 2021;2021:6633700.
- 508 2. Hill MA, Yang Y, Zhang L et al. Insulin resistance, cardiovascular stiffening and
509 cardiovascular disease. *Metabolism* 2021;119:154766.
- 510 3. Li H, Zuo Y, Qian F et al. Triglyceride-glucose index variability and incident cardiovascular
511 disease: a prospective cohort study. *Cardiovasc Diabetol* 2022;21:105.
- 512 4. Zhao Q, Zhang TY, Cheng YJ et al. Triglyceride-Glucose Index as a Surrogate Marker of
513 Insulin Resistance for Predicting Cardiovascular Outcomes in Nondiabetic Patients with Non-
514 ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary
515 Intervention. *J Atheroscler Thromb* 2021;28:1175-1194.
- 516 5. Araujo SP, Juvanhol LL, Bressan J, Hermsdorff HHM. Triglyceride glucose index: A new
517 biomarker in predicting cardiovascular risk. *Prev Med Rep* 2022;29:101941.
- 518 6. Zeng X, Han D, Zhou H et al. Triglyceride-Glucose Index and Homeostasis Model
519 Assessment-Insulin Resistance in Young Adulthood and Risk of Incident Congestive Heart
520 Failure in Midlife: The Coronary Artery Risk Development in Young Adults Study. *Front*
521 *Cardiovasc Med* 2022;9:944258.
- 522 7. Ling Y, Fu C, Fan Q, Liu J, Jiang L, Tang S. Triglyceride-Glucose Index and New-Onset
523 Atrial Fibrillation in ST-Segment Elevation Myocardial Infarction Patients After
524 Percutaneous Coronary Intervention. *Front Cardiovasc Med* 2022;9:838761.
- 525 8. Xu L, Wu M, Chen S et al. Triglyceride-glucose index associates with incident heart failure:
526 A cohort study. *Diabetes Metab* 2022;48:101365.
- 527 9. Hayiroglu MI, Cinar T, Cicek V, Palice A, Ayhan G, Tekkesin AI. The Triglyceride-Glucose
528 Index Can Predict Long-Term Major Adverse Cardiovascular Events in Turkish Patients With
529 High Cardiovascular Risk. *J Lipid Atheroscler* 2022;11:280-287.
- 530 10. Yu B, Mo Y, Hu X et al. Triglyceride-glucose index is associated with quantitative flow ratio
531 in patients with acute ST-elevation myocardial infarction after percutaneous coronary
532 intervention. *Front Cardiovasc Med* 2022;9:1002030.
- 533 11. Luo E, Wang D, Yan G et al. High triglyceride-glucose index is associated with poor
534 prognosis in patients with acute ST-elevation myocardial infarction after percutaneous
535 coronary intervention. *Cardiovasc Diabetol* 2019;18:150.
- 536 12. Sajdeya O, Beran A, Mhanna M et al. Triglyceride Glucose Index for the Prediction of
537 Subclinical Atherosclerosis and Arterial Stiffness: A Meta-analysis of 37,780 Individuals.
538 *Curr Probl Cardiol* 2022;47:101390.
- 539 13. Karadeniz FO, Sancaktepe EA, Karadeniz Y. High Triglyceride-Glucose Index is Associated
540 With Poor Prognosis in Patients With Acute Coronary Syndrome in Long-Term Follow-Up.
541 *Angiology* 2022;33197221124763.
- 542 14. Huang R, Wang Z, Chen J et al. Prognostic value of triglyceride glucose (TyG) index in
543 patients with acute decompensated heart failure. *Cardiovasc Diabetol* 2022;21:88.
- 544 15. Yokoyama R, Kanzaki Y, Watanabe T et al. Prevalence and Risk Factors of Silent Cerebral
545 Microbleeds in Patients with Coronary Artery Disease. *J Stroke Cerebrovasc Dis*
546 2022;31:106211.

- 547 16. Sun M, Guo H, Wang Y, Ma D. Association of triglyceride glucose index with all-cause and
548 cause-specific mortality among middle age and elderly US population. *BMC Geriatr*
549 2022;22:461.
- 550 17. Vahatalo J, Holmstrom L, Pakanen L et al. Coronary Artery Disease as the Cause of Sudden
551 Cardiac Death Among Victims < 50 Years of Age. *Am J Cardiol* 2021;147:33-38.
- 552 18. Chen S, Dong Y, Kiuchi MG et al. Coronary Artery Complication in Kawasaki Disease and
553 the Importance of Early Intervention : A Systematic Review and Meta-analysis. *JAMA*
554 *Pediatr* 2016;170:1156-1163.
- 555 19. Huang L, Pang L, Gu Q et al. Prevalence, risk factors, and survival associated with
556 pulmonary hypertension and heart failure among patients with underlying coronary artery
557 disease: a national prospective, multicenter registry study in China. *Chin Med J (Engl)*
558 2022;135:1837-1845.
- 559 20. Asker M, Asker S, Kucuk U, Kucuk HO, Ozbay B. Relationship between coronary artery
560 disease and pulmonary arterial pressure in patients with chronic obstructive pulmonary
561 disease. *Int J Clin Exp Med* 2014;7:5837-41.
- 562 21. Orfanos SE, Giannakoulas G. Pulmonary Hypertension: Current Diagnosis, Approach and
563 Treatment at the Dawn of the New European Guidelines. *J Clin Med* 2022;11.
- 564 22. Humbert M, Kovacs G, Hoeper MM et al. 2022 ESC/ERS Guidelines for the diagnosis and
565 treatment of pulmonary hypertension. *Eur Respir J* 2022.
- 566 23. Boucly A, Weatherald J, Savale L et al. Risk assessment, prognosis and guideline
567 implementation in pulmonary arterial hypertension. *Eur Respir J* 2017;50.
- 568 24. Yuan Y, Zhang Y, Zhang X et al. Deciphering the genetic and modular connections between
569 coronary heart disease, idiopathic pulmonary arterial hypertension and pulmonary heart
570 disease. *Mol Med Rep* 2016;14:661-70.
- 571 25. Ogiso M, Serizawa N, Kamishima K, Yamaguchi J, Hagiwara N. Percutaneous coronary
572 intervention for left main compression syndrome due to severe idiopathic pulmonary arterial
573 hypertension: one year follow-up using intravascular imaging. *Intern Med* 2015;54:801-4.
- 574 26. Mansour IN, Lang RM, Aburuwaida WM, Bhawe NM, Ward RP. Evaluation of the clinical
575 application of the ACCF/AASE appropriateness criteria for stress echocardiography. *J Am Soc*
576 *Echocardiogr* 2010;23:1199-204.
- 577 27. Gaisl T, Schlatzer C, Schwarz EI et al. Coronary artery calcification, epicardial fat burden,
578 and cardiovascular events in chronic obstructive pulmonary disease. *PLoS One*
579 2015;10:e0126613.
- 580 28. Hirani N, Brunner NW, Kapasi A et al. Canadian Cardiovascular Society/Canadian Thoracic
581 Society Position Statement on Pulmonary Hypertension. *Can J Cardiol* 2020;36:977-992.
- 582 29. Dai Z, Lai G, Chen Z, Li Y, Chen X, Lyu G. Double Doppler Tei index combined with lung
583 ultrasound to evaluate the right ventricular function and lung condition in neonates with
584 pulmonary hypertension. *J Clin Ultrasound* 2022.
- 585 30. Sree Raman K, Shah R, Stokes M et al. Left ventricular ischemia in pre-capillary pulmonary
586 hypertension: a cardiovascular magnetic resonance study. *Cardiovasc Diagn Ther*
587 2020;10:1280-1292.

- 588 31. Boxhammer E, Paar V, Jirak P et al. Main pulmonary artery diameter in combination with
589 cardiovascular biomarkers. New possibilities to identify pulmonary hypertension in patients
590 with severe aortic valve stenosis? *Minerva Med* 2022.
- 591 32. Wilson PW. Diabetes mellitus and coronary heart disease. *Am J Kidney Dis* 1998;32:S89-
592 100.
- 593 33. Zhou Y, Pan Y, Yan H et al. Triglyceride Glucose Index and Prognosis of Patients With
594 Ischemic Stroke. *Front Neurol* 2020;11:456.
- 595 34. Han S, Wang C, Tong F et al. Triglyceride glucose index and its combination with the Get
596 with the Guidelines-Heart Failure score in predicting the prognosis in patients with heart
597 failure. *Front Nutr* 2022;9:950338.
- 598 35. Teng Z, Feng J, Dong Y et al. Triglyceride glucose index is associated with cerebral small
599 vessel disease burden and cognitive impairment in elderly patients with type 2 diabetes
600 mellitus. *Front Endocrinol (Lausanne)* 2022;13:970122.
- 601 36. Ozbicer S, Yuksel G, Deniz Urgun O. Triglyceride glucose index is independently associated
602 with aortic intima-media thickness in patients without known atherosclerotic cardiovascular
603 disease or diabetes. *Diab Vasc Dis Res* 2022;19:14791641221136203.
- 604 37. Emlek N, Aydin C. The relationship between nondipper hypertension and triglyceride glucose
605 index. *Blood Press Monit* 2022.
- 606 38. Zheng R, Mao Y. Triglyceride and glucose (TyG) index as a predictor of incident
607 hypertension: a 9-year longitudinal population-based study. *Lipids Health Dis* 2017;16:175.
- 608 39. Lambrinoudaki I, Kazani MV, Armeni E et al. The TyG Index as a Marker of Subclinical
609 Atherosclerosis and Arterial Stiffness in Lean and Overweight Postmenopausal Women.
610 *Heart Lung Circ* 2018;27:716-724.
- 611 40. Genereux P. Pulmonary Hypertension and Aortic Stenosis: A Piece of the Puzzle. *J Am Coll
612 Cardiol* 2022;80:1614-1616.
- 613 41. Xiong S, Chen Q, Zhang Z et al. A synergistic effect of the triglyceride-glucose index and the
614 residual SYNTAX score on the prediction of intermediate-term major adverse cardiac events
615 in patients with type 2 diabetes mellitus undergoing percutaneous coronary intervention.
616 *Cardiovasc Diabetol* 2022;21:115.
- 617 42. Ozkalayci F, Karagoz A, Karabay CY et al. Prognostic value of triglyceride/glucose index in
618 patients with ST-segment elevation myocardial infarction. *Biomark Med* 2022;16:613-622.
- 619 43. Hijioka N, Kamioka M, Matsumoto Y et al. Clinical impact of insulin resistance on
620 pulmonary vein isolation outcome in patients with paroxysmal atrial fibrillation. *J Cardiovasc
621 Electrophysiol* 2019;30:479-486.
- 622 44. Zamanian RT, Hansmann G, Snook S et al. Insulin resistance in pulmonary arterial
623 hypertension. *Eur Respir J* 2009;33:318-24.
- 624 45. Naderi N, Boobejame P, Bakhshandeh H, Amin A, Taghavi S, Maleki M. Insulin resistance in
625 pulmonary arterial hypertension, is it a novel disease modifier? *Res Cardiovasc Med*
626 2014;3:e19710.
- 627 46. Xu X, Huang R, Lin Y et al. High triglyceride-glucose index in young adulthood is associated
628 with incident cardiovascular disease and mortality in later life: insight from the CARDIA
629 study. *Cardiovasc Diabetol* 2022;21:155.

1 Tables

2 Table 1 The characteristics of the patients

	Overall (n = 247)	Non-PH (n = 225)	PH (n = 22)	p value
Age (years)	68.84±12.12	68.54±12.16	71.91±11.51	0.214
BMI (kg/m ²)	24.10±3.42	24.18±3.49	23.22±	0.206
Gender, female, n (%)	92(37.2%)	85(37.8%)	7(31.8%)	0.581
Smoking, n (%)	104(42.1%)	97(43.1%)	7(31.8%)	0.306
Drinking n (%)	43(17.4%)	40(17.8%)	3(13.6%)	0.775
Cerebral infarction history n (%)	55(22.3%)	46(20.4%)	9(40.9%)	0.028
Hypertension n (%)	158(64%)	144(64.0%)	14(63.6%)	0.490
T2DM, n (%)	70(28.3%)	64(28.4%)	6(27.3%)	0.927
Meditation				
CCB, n (%)	50(20.2%)	45(20.0%)	5(22.7%)	0.573
ACEI/ARB, n (%)	175(70.9%)	161(71.6%)	16(72.7%)	0.475
β-blocker, n (%)	175(70.9%)	161(71.6%)	14(63.6%)	0.884
Diuretic, n (%)	55(22.3%)	50(22.2%)	5(22.7%)	0.784

3
4 The Cerebral infarction history showed significant difference between PH and non-PH groups.

5 ACEI: angiotension converting enzyme inhibitor; ARB: angiotensin receptor blocker; CCB: calcium channel
6 blockers;T2DM: diabetes mellitus type 2.

7
8

9
10

Table 2 Hemodynamics changes from baseline to follow-up

	Baseline	Follow up	p
LAD (mm)	35.69±5.00	35.74±4.59	<0.001
LVDD (mm)	47.02±6.02	47.73±6.08	<0.001
LVEF (%)	61.12±9.91	61.03±8.68	<0.001
SV (ml)	70.32±18.59	70.35±20.06	0.241
RAD (mm)	35.45±4.28	35.38±3.64	<0.001
RVD (mm)	34.02±3.21	33.79±3.82	<0.001
TRA (cm ²)	0.00(0.00-1.00)	0.50(0.00-1.00)	0.127
TRV (m/s)	0.00(0.00-243.00)	200.00(0.00-240.00)	0.573

11
12
13

The parameters of hemodynamics changed significantly from baseline to the follow-up.

14 Table 3 Differences between PH and non-PH patients

	Non-PH patients (n = 225)	PH patients (n = 22)	P value
Echocardiographic parameters			
LAD (mm)	35.52±4.97	37.36±5.09	0.100
LVDD (mm)	46.89±5.71	48.31±8.64	0.290
LVEF (%)	61.29±9.57	59.41±13.084	0.396
SV (ml)	70.04±18.57	73.13±18.91	0.457
RAD (mm)	35.33±2.00	36.68±5.04	0.158
RVD (mm)	33.95±3.15	34.81±3.78	0.226
FS (%)	33.72±7.69	32.23±8.61	0.292
TRA (cm ²)	0.00(0.00-1.00)	0.500(0.00-1.52)	0.512
TRV (m/s)	0.00(0.00-243.38)	100.00(0.00-245.00)	0.736
Biomarkers			
BNP (pg/ml)	68.00 (18.05-196.00)	174.00 (76.25-447.75)	0.007
TNI (ng/ml)	0.05(0.05-0.05)	0.05(0.05-0.05)	0.307
MYO (ng/ml)	56.30 (42.65-77.25)	76.30(64.38-126.35)	<0.001
CK-MB (ng/ml)	1.00(1.00-1.00)	1.00(1.00-1.00)	0.808
Electrolytes			
Mg ²⁺ (mmol/L)	0.966±0.132	0.95±0.116	0.700
K ⁺ (mmol/L)	3.98±0.73	3.90±0.47	0.642
Ca ²⁺ (mmol/L)	2.200 (2.12-2.30)	2.18 (2.11-2.26)	0.705
Na ⁺ (mmol/L)	139.38±4.80	139.34±3.88	0.970
Cl ⁻ (mmol/L)	105.68±5.08	104.97±3.96	0.552
TCO ₂ (mmol/L)	24.70±5.87	25.14±2.44	0.732
P (mmol/L)	1.11±0.49	1.08±0.30	0.843
Renal function			
UA(μmol/L)	369.70 (304.55-442.30)	355.05 (282.30-444.47)	0.668
Cr (μmol/L)	78.30 (67.30-93.85)	79.95 (68.45-93.90)	0.818
BUN (μmol/L)	7.12±6.38	7.77±4.57	0.645
eGFR(mL/min/1.73m ²)	81.12 (61.10-92.44)	78.88 (60.25-85.46)	0.445
Serum lipids and glucose			
TC (mmol/L)	3.74(2.96-4.52)	3.72 (2.97-4.19)	0.597
TG (mmol/L)	1.25 (0.92-1.80)	1.49 (0.35-2.42)	0.541
HDL-C (mmol/L)	1.06 (0.870-1.26)	0.915 (0.770-1.071)	0.033
LDL-C (mmol/L)	2.31 (1.74-2.96)	2.215 (1.780-2.59)	0.433
Glu (mmol/L)	4.74 (4.20-5.52)	5.32 (4.32-6.48)	0.126
TyG index	6.95(6.47-7.36)	7.15(6.49-7.96)	0.202
HbA1c (%)	6.30(5.90-6.75)	6.48 (6.075-7.00)	0.220
Basic parameters			
HR (mmHg)	72.54±14.50	76.20±22.01	0.285
SBP (mmHg)	127.55±19.24	125.92±17.63	0.702

DBP (mmHg)	72.67±13.06	72.03±12.91	0.828
------------	-------------	-------------	-------

15
16 HDL-C showed significant difference between PH and non-PH groups. However, the TyG index showed no
17 significant differences between them.
18

19 Table 4 Relationship between sPAP and other paramters

	Correlation coefficient r	P value
<i>Demographic data</i>		
Age (years)	0.071	0.264
BMI ((kg/m ²))	-0.009	0.884
<i>Echocardiographic parameters</i>		
LAD (mm)	0.110	0.083
LVDD (mm)	0.060	0.347
LVEF (%)	0.071	0.268
SV (ml)	0.032	0.618
RAD (mm)	0.095	0.138
RVD (mm)	0.092	0.149
FS (%)	0.069	0.283
TRA (cm ²)	0.151	0.017
TRV (m/s)	0.156	0.014
<i>Biomarkers</i>		
BNP (pg/ml)	0.113	0.078
TNI (ng/ml)	-0.041	0.519
MYO (ng/ml)	0.109	0.089
CK-MB (ng/ml)	0.040	0.531
<i>Electrolytes</i>		
Mg ²⁺ (mmol/L)	0.034	0.490
K ⁺ (mmol/L)	-0.006	0.924
Ca ²⁺ (mmol/L)	0.049	0.440
Na ⁺ (mmol/L)	-0.059	0.352
Cl ⁻ (mmol/L)	-0.074	0.247
TCO ₂ (mmol/L)	0.061	0.338
P (mmol/L)	-0.064	0.318
<i>Renal function</i>		
UA(μmol/L)	-0.003	0.968
Cr (μmol/L)	-0.010	0.880
BUN (μmol/L)	0.029	0.650
eGFR(mL/min/1.73m ²)	0.053	0.405
<i>Serum lipids and glucose</i>		
TC (mmol/L)	-0.089	0.166
TG (mmol/L)	-0.105	0.099
HDL-C (mmol/L)	-0.041	0.526
LDL-C (mmol/L)	-0.117	0.066
Glu (mmol/L)	-0.024	0.703
TyG index	-0.095	0.136

HbA1c (%)	-0.027	0.6720
Basic parameters		
HR (bpm)	-0.034	0.592
SBP (mmHg)	-0.070	0.271
DBP (mmHg)	-0.087	0.173

21
22
23
24

Baselines of TRA and TRV were closely correlated to the followed-up sPAP.

25 Table 5 Univariate logistics regression for PH
26

	β	p	OR	95%CI	
<i>Demographic data</i>					
Age (years)	0.025	0.214	1.025	0.986	1.066
BMI (kg/m ²)	-0.087	0.204	0.917	0.802	1.048
Gender, female, n (%)	-0.263	0.582	0.769	0.301	1.961
smoking, n (%)	-0.485	0.310	0.616	0.242	1.569
Drinking n (%)	-0.314	0.626	0.730	0.206	2.587
Cerebral infarction history	0.991	0.033	2.694	1.085	6.690
Hypertension n (%)	-0.016	0.973	0.984	0.396	2.446
T2DM, n (%)	-0.058	0.907	0.943	0.353	2.518
<i>Meditation</i>					
CCB, n (%)	0.163	0.761	1.176	0.412	3.359
ACEI/ARB, n (%)	0.102	0.839	1.107	0.415	2.953
β -blocker, n (%)	-0.363	0.437	0.696	0.278	1.738
Diuretic, n (%)	0.029	0.957	1.029	0.362	2.928
<i>Echocardiographic parameters</i>					
LAD (mm)	0.074	0.095	1.077	0.987	1.174
LVDD (mm)	0.035	0.291	1.035	0.971	1.105
LVEF (%)	-0.017	0.396	0.983	0.944	1.023
SV (ml)	0.009	0.456	1.009	0.986	1.032
RAD (mm)	0.055	0.172	1.057	0.976	1.144
RVD (mm)	0.073	0.227	1.076	0.955	1.212
FS (%)	-0.029	0.378	0.972	0.912	1.036
TRA (cm ²)	0.111	0.476	1.117	0.823	1.516
TRV (m/s)	0.001	0.818	1.000	0.997	1.004
<i>Biomarkers</i>					
BNP (pg/ml)	0.001	0.357	1.000	1.000	1.001
TNI (ng/ml)	-0.215	0.680	0.807	0.290	2.243
MYO (ng/ml)	0.007	0.024	1.007	1.001	1.013
CK-MB (ng/ml)	-0.083	0.642	0.920	0.649	1.306
<i>Electrolytes</i>					
Mg ²⁺ (mmol/L)	-0.796	0.696	0.451	0.008	24.579
K ⁺ (mmol/L)	-0.185	0.639	0.831	0.383	1.803
Ca ²⁺ (mmol/L)	-0.281	0.825	0.755	0.063	9.066
Na ⁺ (mmol/L)	0.014	0.639	1.014	0.957	1.075
Cl ⁻ (mmol/L)	-0.031	0.514	0.970	0.884	1.063
TCO ₂ (mmol/L)	0.011	0.733	1.011	0.950	1.076
P (mmol/L)	-0.123	0.844	0.884	0.261	2.995
<i>Renal function</i>					
UA (μ mol/L)	0.001	0.829	1.000	0.997	1.004
Cr (μ mol/L)	-0.004	0.581	0.996	0.984	1.009
BUN (μ mol/L)	0.013	0.649	1.013	0.958	1.070
eGFR (mL/min/1.73m ²)	-0.002	0.829	0.998	0.978	1.018
<i>Serum lipids and glucose</i>					

Baseline TyG predicts PH

TC (mmol/L)	-0.185	0.391	0.831	0.545	1.268
TG (mmol/L)	0.304	0.015	1.355	1.062	1.730
HDL-C (mmol/L)	-1.744	0.065	0.175	0.027	1.115
LDL-C (mmol/L)	-0.315	0.275	0.730	0.414	1.285
Glu (mmol/L)	0.180	0.066	1.198	0.988	1.451
TyG index	0.628	0.005	2.389	1.308	4.363
HbA1c (%)	0.288	0.071	1.334	0.975	1.825
Basic parameters					
HR (bpm)	0.014	0.287	1.014	0.989	1.039
SBP (mmHg)	-0.005	0.701	0.995	0.972	1.019
DBP (mmHg)	-0.004	0.827	0.996	0.963	1.030

Primarily screen for the predictors for PH.

27
28
29

30 Table 6 Adjusted logistic regression for PH in CAD patients after PCI treatments

	β	p	OR	95%CI	
Cerebral infarction history	0.990	0.039	2.690	1.054	6.871
TyG index	0.636	0.048	1.889	1.006	3.546
MYO	0.006	0.044	1.006	1.000	1.012

31
32 Three of the above parameters were independent predictors of PH

33

34